Pharma Partnering Contacts

At Roche and Genentech, we are leveraging our unique company structure and culture to build deep and long-lasting collaborations with our partners to translate pioneering science into breakthroughs for patients.

We strongly believe that the key elements to a successful and lasting partnership are trust, shared values and openness. To revolutionize today’s standard of care, we are looking for best or first in class innovation in the following areas:

Cardiovascular & Metabolic Disease

We are highly committed to making a contribution to areas of huge unmet need and societal burden through transformative science and expands its footprint in cardiovascular and metabolic diseases.

Partnering opportunities we are looking for:

  • Uncontrolled hypertension

  • Obesity  (also in context of Diabetes)

  • MASH (metabolic dysfunction-associated steatohepatitis)

  • Myocardial infarction/ stroke secondary prevention

  • Cardiomyopathies

  • SPAF (stroke & systemic embolic prevention in atrial fibrillation)

Digital and Personalised Healthcare (PHC)

We are interested in collaborations on real world data, advanced analytics, digital tools and platform opportunities that:

  • Enable infrastructure 

  • Expand our portfolio (novel targets, line extensions, combinations, etc.)

  • Improve PTS and cycle times

  • Increase product potential


We are leading the way to advance science in inflammatory and autoimmune diseases.

Partnering opportunities we are looking for:

  • Gastroenterology (IBD), Respiratory (COPD, Asthma, IPF, ILD, SSc), Nephrology (GN, CKD, Transplant, auto-immune skin diseases (Psoriasis, AD), T1D, Celiac disease

    • Innate, Adaptive, Fibrosis, Tolerance and Tissue Regeneration Targets

Infectious Diseases

We are advancing innovation to combat infectious diseases like HBV, influenza and MDR.

Partnering opportunities we are looking for:

  • Hepatitis B

  • Multidrug-resistant, Gram-negative Bacterial Infections


We focus on advances for neurodegenerative, psychiatric and neurodevelopmental disorders.

Partnering opportunities we are looking for:

  • Neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease, Huntington disease)

  • Neuroinflammation (e.g. Multiple sclerosis)

  • Neuromuscular diseases (e.g. ALS, Duchenne Muscular Dystrophy)

  • Neurodevelopment (e.g. ASD)

  • Stroke

Oncology and Cancer Immunotherapy

We focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy.

Partnering opportunities we are looking for:

  • Oncogenic drivers

  • DNA Damage Response/ Synthetic lethality

  • Antibody Drug Conjugates

  • Adaptive and innate immunity

  • Neoantigens

  • Stromal biology

  • Cell therapies


We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research.

Partnering opportunities we are looking for:

  • Retinal diseases and long-acting ocular drug delivery solutions

  • Glaucoma and dry eye disease

Research Technologies

We focus on therapeutic modalities and enabling technologies.

Partnering opportunities we are looking for:

  • Novel modalities and enabling technologies to expand the druggable target space

  • Targeted or intracellular delivery

  • Artificial intelligence for target and drug discovery

  • Genomic Medicine platforms

Pharma Partnering in Asia

Research & Development is the essence and lifeblood of Roche - and we have a unique way to foster innovation together with our partners in Asia and across the world. Partnering opportunities we are looking for:

  • Innovative biotechs or academic institutions from Asia working on first in class or best in disease opportunities from Discovery to Phase II Development and;

  • Immunology (interferon-driven inflammatory diseases including lupus nephritis and systemic sclerosis, nephrology and renal transplant, with focused MoAs in nucleic acid sensing, interferon production, complement and immune tolerance) and oncology (gastrointestinal cancers, with focused MoAs in novel and/or disease-specific cancer driver genes, synthetic lethality, immunotherapy for enhancing innate immunity and dampening suppression, and cancer extracellular matrix esp. collagen modulation)

Leveraging external innovation has always been central to our R&D strategy and, as such, supporting, encouraging and accessing early stage innovation is a critical aspect of our ability to discover and develop meaningful medicines for patients. Since some of the most cutting-edge science is happening in the UK, we are increasingly focusing on identifying and supporting great science in the UK. We are seeking partnering opportunities across all our therapeutic areas of interest, including digital and personalised healthcare and novel research technologies, in particular for the following:

  • Novel targets

  • Potential first- or best-in class molecules

  • Novel enabling modalities

  • Data sets and advanced analytics

  • Digital and mobile technologies

During the collaboration conversations, a dedicated Alliance Director is assigned as the single point of contact to ensure successful continuation and an enduring relationship with our new partner.

Out-licensing and divestment decisions enable us to continue our investment in innovative R&D, supporting the development of novel medicines. In addition,it supports the further development of programs that could result in treatments for patients in disease areas and indications that are no longer of strategic focus for Roche and Genentech.

Related links

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statement